Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Maximizing the value of diagnostics in Alzheimer's disease drug development

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Profit and loss calculation for a hypothetical AD therapy.

References

  1. Hurko, O. & Jones, G. K. Valuation of biomarkers. Nature Rev. Drug Discov. 10, 253–254 (2011).

    Article  CAS  Google Scholar 

  2. Boise, L. et al. Dementia assessment in primary care: results from a study in three managed care systems. J. Gerontol. A Biol. Sci. Med. Sci. 59, M621–M626 (2004).

    Article  Google Scholar 

  3. Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Rev. Drug Discov. 9, 560–574 (2010).

    Article  CAS  Google Scholar 

  4. Beckett, L. A. et al. The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 6, 257–264 (2010).

    Article  Google Scholar 

  5. Dimasi, J. A. et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eric M. Snyder.

Ethics declarations

Competing interests

Eric M. Snyder is an employee of Leerink Swann Consulting LLC, which serves a large number of pharmaceutical and biotech clients worldwide.

Frank S. David is an employee of Leerink Swann Consulting LLC, a life sciences consultancy that serves a large number of biopharmaceutical, medical technology, tools and diagnostics companies worldwide.

Jake Olin is an employee of Leerink Swann Consulting LLC, a life sciences consultancy that serves a large number of biopharmaceutical, medical technology, tools and diagnostics companies worldwide.

Supplementary information

Supplementary information S1

Impact of a diagnostic on the profit and loss calculation for an AD therapy (PDF 601 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Snyder, E., Olin, J. & David, F. Maximizing the value of diagnostics in Alzheimer's disease drug development. Nat Rev Drug Discov 11, 183–184 (2012). https://doi.org/10.1038/nrd3535

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3535

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research